机构：[1]Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China重点科室诊疗科室神经外科神经外科首都医科大学附属天坛医院[2]China National Clinical Research Center for Neurological Diseases, Beijing 100070, China[3]Beijing Neurosurgical Institution, Capital Medical University, Beijing 100050, China研究所北京市神经外科研究所首都医科大学附属天坛医院[4]Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing 100191, China[5]Department of Cell Biology, Peking University Health Science Center, Beijing 100191, China[6]Peking University Stem Cell Research Center, Beijing 100191, China.
Objective: To determine the prognostic implications and clinical significance of epidermal growth factor receptor variant III (EGFRvIII) expression and EGFRvIII nuclear translocation in Chinese human gliomas. Methods: We retrospectively examined EGFRvIII expression and EGFRvIII nuclear translocation using immunohistochemistry in specimens of 240 Chinese patients with glioma, including 84 World Health Organization (WHO) II gliomas, 84 WHO III gliomas and 72 glioblastomas (WHO IV). Factors that correlated with EGFRvIII and EGFRvIII nuclear translocation expression were analyzed by the Chi-square test. Kaplan-Meier methodology and Cox regression were used for the survival analysis. Results: Log-rank tests showed that patient age, Karnofsky performance scale (KPS) score, tumor grade, EGFRvIII expression, EGFRvIII nuclear translocation, 1p/19q codeletion, isocitrate dehydrogenase (IDH) mutation, Ki-67 labeling index and O6-methylguanine-DNA methyltransferase (MGMT) status (P<0.05) were significantly correlated with overall survival (OS) time. Multivariate Cox regression analysis revealed that patient age, tumor grade, EGFRvIII nuclear translocation, 1p/19q codeletion, and IDH mutation (P<0.05) were significantly correlated with OS. Patients with a high level of EGFRvIII nuclear translocation (>= 7%) had both significantly shorter OS [hazard ratio (HR): 1.920, 95% confidence interval (95% CI): 1.228-3.003, P=0.004] and progression-free survival (PFS) times (HR: 1.661, 95% CI: 1.116-2.471, P=0.012) than those with a low level of EGFRvIII nuclear translocation (<7%). Conclusions: A high level of EGFRvIII nuclear translocation in glioma is an independent factor indicating a poor prognosis, but EGFRvIII expression is not an independent clinical prognostic factor. The level of EGFRvIII nuclear translocation maybe a novel and crucial prognostic biomarker in glioma.
基金：
National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81771309]
第一作者机构：[1]Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China[2]China National Clinical Research Center for Neurological Diseases, Beijing 100070, China[3]Beijing Neurosurgical Institution, Capital Medical University, Beijing 100050, China
共同第一作者：
通讯作者：
通讯机构：[1]Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China[2]China National Clinical Research Center for Neurological Diseases, Beijing 100070, China[3]Beijing Neurosurgical Institution, Capital Medical University, Beijing 100050, China[*1]Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing 100070, China.
推荐引用方式(GB/T 7714)：
Kaiyuan Yang,Xiaohui Ren,Liyuan Tao,et al.Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas[J].CHINESE JOURNAL OF CANCER RESEARCH.2019,31(1):188-202.doi:10.21147/j.issn.1000-9604.2019.01.14.
APA：
Kaiyuan Yang,Xiaohui Ren,Liyuan Tao,Peipei Wang,Haihui Jiang...&Song Lin.(2019).Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas.CHINESE JOURNAL OF CANCER RESEARCH,31,(1)
MLA：
Kaiyuan Yang,et al."Prognostic implications of epidermal growth factor receptor variant III expression and nuclear translocation in Chinese human gliomas".CHINESE JOURNAL OF CANCER RESEARCH 31..1(2019):188-202
